Boston Scientific Corporation $BSX Stake Boosted by IFM Investors Pty Ltd

IFM Investors Pty Ltd grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 4.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 324,188 shares of the medical equipment provider’s stock after acquiring an additional 14,062 shares during the period. IFM Investors Pty Ltd’s holdings in Boston Scientific were worth $30,911,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. Capital World Investors boosted its holdings in Boston Scientific by 1.9% in the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after purchasing an additional 502,627 shares in the last quarter. Norges Bank bought a new stake in Boston Scientific in the fourth quarter worth $2,199,395,000. Invesco Ltd. boosted its holdings in Boston Scientific by 0.7% in the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock worth $1,656,131,000 after purchasing an additional 111,826 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Boston Scientific by 0.9% in the third quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock worth $1,406,129,000 after purchasing an additional 128,188 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 9,800 shares of company stock valued at $554,012. Insiders own 0.34% of the company’s stock.

Boston Scientific Stock Down 2.3%

Shares of BSX opened at $47.22 on Friday. The company has a 50-day simple moving average of $56.68 and a 200-day simple moving average of $75.14. The firm has a market capitalization of $70.18 billion, a P/E ratio of 19.76, a P/E/G ratio of 0.91 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52 week low of $46.91 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has initiated a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

BSX has been the subject of a number of recent research reports. Leerink Partners decreased their price objective on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a report on Thursday, May 28th. Weiss Ratings cut shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. BTIG Research decreased their price objective on shares of Boston Scientific from $80.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, June 2nd. Bank of America decreased their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a report on Monday, May 18th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $77.00 price objective on shares of Boston Scientific in a report on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $85.92.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: BTIG reiterated a bullish view on Boston Scientific, highlighting a low forward P/E and significant upside potential, which may help support the stock after its sharp year-to-date de-rating. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Recent analyst commentary still shows broad Wall Street support, with several buy ratings and price targets well above the current trading range, suggesting some investors see the selloff as overdone.
• Neutral Sentiment: Boston Scientific’s Q1 results beat estimates slightly, with revenue up 11.6% year over year, but the market appears more focused on forward guidance and segment-level growth trends than the last quarter’s results.
• Neutral Sentiment: Erste Group trimmed FY2026 and FY2027 EPS estimates only modestly, signaling little change to the core earnings outlook, though the revisions add to the cautious tone around near-term expectations.
• Negative Sentiment: The stock has been sliding after a guidance reduction and renewed scrutiny over slower growth in important businesses, including WATCHMAN and ablation technologies, which is weighing on investor confidence. Boston Scientific Stock (BSX) Opinions on Recent Stock Decline
• Negative Sentiment: A recent market update showed BSX declined again in the latest session, reinforcing the bearish momentum that has followed the guidance-related selloff. Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.